Tissue Factor Inhibitor Fast Tracked for COVID-19
AB201 is a small recombinant protein that selectively inhibits tissue factor, which has been shown to play a role in the inflammatory response associated with viral infections.
COVID19
WHO: Remdesivir Not Advised for Hospitalized COVID-19 Patients
Evidence to date has not shown clinically important effects on mortality, need for mechanical ventilation
Vaccine Candidate AZD1222 Effective Against COVID-19
A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.
Antibody Cocktail for COVID-19 Gets Emergency Use Authorization
The investigational treatment from Regeneron consists of 2 potent, virus-neutralizing antibodies.
FDA Issues EUA to Baricitinib Plus Remdesivir for Hospitalized COVID-19 Patients
The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.
Pfizer, BioNTech to Submit EUA Request for COVID-19 Vaccine Candidate
Pfizer and BioNTech will submit an Emergency Use Authorization (EUA) request to the FDA for their mRNA-based vaccine candidate BNT162b2 against COVID-19.
Fluvoxamine Evaluated in Patients With Mild COVID-19
The study, which was fully remote and contactless, aimed to evaluate whether early treatment with fluvoxamine reduced the likelihood of clinical deterioration and disease severity in patients with mild COVID-19 illness.
MPR Weekly Dose Podcast Episode 59
The latest on the vaccine development from Moderna, and BioNTech and Pfizer as they release more trial data; An at-home diagnostic test is approved; Keytruda gains expanded approval; And all the rest of the drug news from this past week.
FDA Authorizes COVID-19 Test That Provides Rapid Results at Home
This is the first time the Agency has authorized a COVID-19 diagnostic test that provides rapid results at home.
Final Analysis Reveals COVID-19 Vaccine Candidate BNT162b2 95% Effective
The analysis of the primary outcomes was based on 170 confirmed cases of COVID-19.
